Nonviral gene transfer strategies for the vasculature

Microcirculation

Volumn 9, Issue 1, 2002, Pages 35-50

  Young, Jennifer L ^a   Dean, David A ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYRIBOZYME;

ANIMAL; BLOOD VESSEL; ELECTROPORATION; GENE TRANSFER; GENE VECTOR; GENETIC TRANSFECTION; HUMAN; METABOLISM; METHODOLOGY; REVIEW; STANDARD;

ANIMALS; BLOOD VESSELS; DNA, CATALYTIC; ELECTROPORATION; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; TRANSFECTION;

EID: 0036363046     PISSN: 10739688     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mn.7800120     Document Type: Article

References (83)

1. 1 Aird WC, Edelberg JM, Weiler‐Guettler H., Simmons WW, Smith TW, Rosenberg RD. (1997). Vascular bed‐specific expression of an endothelial cell gene is programmed by the tissue microenvironment. J Cell Biol 138: 1117–1124.
2. 2 Anderson WF. (1992). Human gene therapy. Science 256: 808–813.
3. 3 Armeanu S., Pelisek J., Krausz E., Fuchs A., Groth D., Curth R., Keil O., Quilici J., Rolland PH, Reszka R., Nikol S.. (2000). Optimization of nonviral gene transfer of vascular smooth muscle cells in vitro and in vivo. Mol Ther 1: 366–375.
4. 4 Ausubel FM, Brent R., Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K.. (1994). Current Protocols Mol Biol. New York: John Wiley & Sons.
5. 5 Barron LG, Uyechi LS, Szoka, FC, Jr. (1999). Cationic lipids are essential for gene delivery mediated by intravenous administration of lipoplexes. Gene Ther 6: 1179–1183.
6. 6 Barron LG, Meyer KB, Szoka FC Jr. (1998). Effects of complement depletion on the pharmacokinetics and gene delivery mediated by cationic lipid‐DNA complexes. Hum Gene Ther 9: 315–323.
7. 7 Baumgartner I., Isner J.. (2001). Somatic gene therapy in the cardiovascular system. Annu Rev Physiol 63: 427–450.
8. 8 Blair‐Parks K., Weston BC, Dean DA. (2002). Gene delivery to the cornea by plasmid injection and electroporation. J Gene Med DOI 10.1002/jgm.231.
9. 9 Buus CL, Aalkjaer C., Nilsson H., Juul B., Moller JV, Mulvany MJ. (1998). Mechanisms of Ca2+ sensitization of force production by noradrenaline in rat mesenteric small arteries. J Physiol 510: 577–590.
10. 10 Campbell AI, Kuliszewski MA, Stewart DJ. (1999). Cell‐based gene transfer to the pulmonary vasculature: endothelial nitric oxide synthase overexpression inhibits monocrotaline‐induced pulmonary hypertension. Am J Respir Cell Mol Biol 21: 567–575.
11. 11 Chang MW, Barr E., Seltzer J., Jiang Y., Nabel GJ, Nabel EG, Parmacek MS, Leiden JM. (1995). Cyto‐static gene therapy for vascular proliferation disorders with a constitutively active form of the retinoblastoma gene product. Science 267: 518–522.
12. 12 Chen L., Daum G., Forough R., Clowes M., Walter U., Clowes AW. (1998). Overexpression of human endothelial nitric oxide synthase in rat vascular smooth muscle cells and in balloon‐injured carotid artery. Circ Res 82: 862–870.
13. 13 Dean DA. (1997). Import of plasmid DNA into the nucleus is sequence specific. Exp Cell Res 230: 293–302.
14. 14 Dean DA, Dean BS, Muller S., Smith LC. (1999). Sequence requirements for plasmid nuclear entry. Exp Cell Res 253: 713–722.
15. 15 Dzau VJ, Mann MJ, Morishita R., Kaneda Y.. (1996). Fusigenic viral liposome for gene therapy in cardio‐vascular disease. Proc Natl Acad Sci USA 93: 11421–11425.
16. 16 Eto Y., Shimokawa H., Hiroki J., Morishige K., Kandabashi T., Matsumoto Y., Amano M., Hoshijima M., Kaibuchi K., Takeshita A.. (2000). Gene transfer of dominant negative Rho kinase suppresses neointimal formation after balloon injury in pigs. Am J Physiol Heart Circ Physiol 278: H1744–H1750.
17. 17 Ferreira V., Assouline Z., Schwachtgen JL, Bahnak BR, Meyer D., Kerbiriou‐Nabias D.. (1993). The role of the 5′‐flanking region in the cell‐specific transcription of the human von Willebrand factor gene. Biochem J 293: 641–648.
18. 18 Fisher KD, Ulbrich K., Subr V., Ward CM, Mautner V., Blakey D., Seymour LW. (2000). A versatile system for receptor‐mediated gene delivery permits increased entry of DNA into target cells, enhanced delivery to the nucleus and elevated rates of transgene expression. Gene Ther 7: 1337–1343.
19. 19 Flugelman MY, Jaklitsch MT, Newman KD, Casscells W., Bratthauer GL, Dichek DA. (1992). Low level in vivo gene transfer into the arterial wall through a perforated balloon catheter. Circulation 85: 1110–1117.
20. 20 French BA, Mazur W., Ali NM, Geske RS, Finnigan JP, Rodgers GP, Roberts R., Raizner AE. (1994). Percutaneous transluminal in vivo gene transfer by recombinant adenovirus in normal porcine coronary arteries, atherosclerotic arteries, and two models of coronary restenosis. Circulation 90: 2402–2413.
21. 21 Genot EM, Parker PJ, Cantrell DA. (1995). Analysis of the role of protein kinase C‐alpha, ‐epsilon, and ‐zeta in T cell activation. J Biol Chem 270: 9833–9839.
22. 22 Harper JW, Adami GR, Wei N., Keyomarsi K., Elledge SJ. (1993). The p21 Cdk‐interacting protein Cip1 is a potent inhibitor of G1 cyclin‐dependent kinases. Cell 75: 805–816.
23. 23 Iiri T., Bell SM, Baranski TJ, Fujita T., Bourne HR. (1999). A G sα mutant designed to inhibit receptor signalling through G s. Proc Natl Acad Sci USA 96: 499–504.
24. 24 Isner JM. (1998). Arterial gene transfer of naked DNA for therapeutic angiogenesis: early clinical results. Adv Drug Deliv Rev 30: 185–197.
25. 25 Kay MA, Glorioso JC, Naldini L.. (2001). Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 7: 33–40.
26. 26 Kerr WG, Mulé JJ. (1994). Gene therapy: current status and future prospects. J Leukoc Biol 56: 210–214.
27. 27 Kircheis R., Wightman L., Schreiber A., Robitza B., Rossler V., Kursa M., Wagner E.. (2001). Polyethylenimine/DNA complexes shielded by transferrin target gene expression to tumors after systemic application. Gene Ther 8: 28–40.
28. 28 Kovacs AM, Zimmer WE. (1993). Molecular cloning and expression of the chicken smooth muscle γ‐actin mRNA. Cell Motil Cytoskeleton 24: 67–81.
29. 29 Kullo IJ, Simari RD, Schwartz RS. (1999). Vascular gene transfer: from bench to bedside. Arterioscler Thromb Vasc Biol 19: 196–207.
30. 30 Labhesetwar V., Bonadio J., Goldstein S., Chen W., Levy RJ. (1998). A DNA controlled‐release coating for gene transfer: transfection in skeletal and cardiac muscle. J Pharm Sci 87: 1347–1350.
31. 31 Laitinen M., Hartikainen J., Hiltunen MO, Eranen J., Kiviniemi M., Narvanen O., Makinen K., Manninen H., Syvanne M., Martin JF, Laakso M., Yla‐Herttuala S.. (2000). Catheter‐mediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty. Hum Gene Ther 11: 263–270.
32. 32 Lee ME, Block KD, Clifford JA, Quertermous T.. (1990). Functional analysis of the endothelin‐1 gene promoter: evidence for an endothelial cell‐specific cisacting sequence. J Biol Chem 265: 10446–10450.
33. 33 Lee SW, Trapnell BC, Rade JJ, Virmani R., Dichek DA. (1993). In vivo adenoviral vector mediated gene transfer into balloon‐injured rat carotid arteries. Circ Res 73: 797–807.
34. 34 Lewis PF, Emerman M.. (1994). Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J Virol 68: 510–516.
35. 35 Li L., Liu Z., Mercer B., Overbeek P., Olson EN. (1997). Evidence for serum response factor‐mediated regulatory networks governing SM22alpha transcription in smooth, skeletal, and cardiac muscle cells. Dev Biol 187: 311–321.
36. 36 Li S., Huang L.. (1997). In vivo gene transfer via intravenous administration of cationic lipid‐protamine‐DNA (LPD) complexes. Gene Ther 4: 891–900.
37. 37 Li S., MacLaughlin FC, Fewell JG, Gondo M., Wang J., Nicol F., Dean DA, Smith LC. (2001). Muscle‐specific enhancement of gene expression by incorporation of the SV40 enhancer in the expression plasmid. Gene Ther 8: 494–497.
38. 38 Liu D., Knapp JE, Song YK. (1999). Mechanisms of cationic liposome‐mediated transfection of the lung endothelium. In: Huang L., Hung M‐C, Wagner E., editors. Nonviral Vectors for Gene Therapy. San Diego: Academic Press, p 314–337.
39. 39 Liu F., Song Y., Liu D.. (1999). Hydrodynamics‐based transfection in animals by systemic administration of plasmid DNA. Gene Ther 6: 1258–1266.
40. 40 Manabe I., Owens GK. (2001). CArG elements control smooth muscle subtype‐specific expression of smooth muscle myosin in vivo. J Clin Invest 107: 823–834.
41. 41 Mann MJ, Whittemore AD, Donaldson MC, Belkin M., Conte MS, Polak JF, Orav EJ, Ehsan A., Dell'Acqua G., Dzau VJ. (1999). Ex vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single‐centre, randomised, controlled trial. Lancet 354: 1493–1498.
42. 42 Martin JB, Young JL, Benoit JN, Dean DA. (2000). Gene transfer to intact mesenteric arteries by electroporation. J Vasc Res 37: 372–380.
43. 43 Masuo M., Reardon S., Ikebe M., Kitazawa T.. (1994). A novel mechanism for the Ca (2+)‐sensitizing effect of protein kinase C on vascular smooth muscle: inhibition of myosin light chain phosphatase. J Gen Physiol 104: 265–286.
44. 44 Matsumoto T., Komori K., Shoji T., Kuma S., Kume M., Yamaoka T., Mori E., Furuyama T., Yonemitsu Y., Sugimachi K.. (2001). Successful and optimized in vivo gene transfer to rabbit carotid artery mediated by electronic pulse. Gene Ther 8: 1174–1179.
45. 45 Miller DG, Adam MA, Miller AD. (1990). Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 10: 4239–4242.
46. 46 Mir LM, Bureau MF, Gehl J., Rangara R., Rouy D., Caillaud J‐M, Delaere P., Branellec D., Schwartz B., Scherman D.. (1999). High‐efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc Natl Acad Sci USA 96: 4262–4267.
47. 47 Mulligan RC. (1993). The basic science of gene therapy. Science 260: 926–932.
48. 48 Ogris M., Brunner S., Schuller S., Kircheis R., Wagner E.. (1999). PEGylated DNA/transferrin‐PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery [In Process Citation]. Gene Ther 6: 595–605.
49. 49 Ohno T., Gordon D., San H., Pompili VJ, Imperiale MJ, Nabel GJ, Nabel EG. (1994). Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science 265: 781–784.
50. 50 Owens GK, Loeb A., Gordon D., Thompson MM. (1986). Expression of smooth muscle‐specific α‐isoactin in cultured vascular smooth muscle cells: relationship between growth and cytodifferentiation. J Cell Biol 102: 343–352.
51. 51 Parker SE, Vahlsing HL, Serfilippi LM, Franklin CL, Doh SG, Gromkowski SH, Lew D., Manthorpe M., Norman J.. (1995). Cancer gene therapy using plasmid DNA: safety evaluation in rodents and non‐human primates [see comments]. Hum Gene Ther 6: 575–590.
52. 52 Patterson C., Perrella MA, Hsieh CM, Yoshizumi M., Lee ME, Haber E.. (1995). Cloning and functional analysis of the promoter for KDR/flk‐1, a receptor for vascular endothelial growth factor. J Biol Chem 270: 23111–23118.
53. 53 Safinya C., Koltover I.. (1999). Self‐assembled structures of lipid DNA nonviral gene delivery systems from synchontron X‐ray diffraction. In: Huang L., Hung M‐C, Wagner E., editors. Nonviral Vectors for Gene Therapy. San Diego: Academic Press, p 92–119.
54. 54 Samaha F., Ip JHS, Morrisey E., Seltzer J., Tang Z., Solway J., Parmacek M.. (1996). Developmental pattern of expression and genomic organization of the calponin‐hi gene. J Biol Chem 271: 395–403.
55. 55 Santiago FS, Lowe HC, Kavurma MM, Chesterman CN, Baker A., Atkins DG, Khachigian LM. (1999). New DNA enzyme targeting Egr‐1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury. Nat Med 5: 1438.
56. 56 Santoro SW, Joyce GF. (1997). A general purpose RNA‐cleaving DNA enzyme. Proc Natl Acad Sci USA 94: 4262–4266.
57. 57 Santoro SW, Joyce GF. (1998). Mechanism and utility of an RNA‐cleaving DNA enzyme. Biochemistry 37: 13330–13342.
58. 58 Schachtner SK, Rome JJ, Hoyt RF, Newman KD, Virmani R., Dichek DA. (1995). In vivo Adenovirus‐mediated gene transfer via the pulmonary artery of rats. Circ Res 76: 701–709.
59. 59 Schulick AH, Newman KD, Virmani R., Dichek DA. (1995). In vivo gene transfer into injured carotid arteries: optimization and evaluation of acute toxicity. Circulation 91: 2407–2414.
60. 60 Sebestyen MG, Wolff JA. (1999). Nuclear transport of exogenous DNA. In: Huang L., Hung M‐C, Wagner E., editors. Nonviral Vectors for Gene Therapy. San Diego: Academic Press, p 140–169.
61. 61 Simari RD, San H., Rekhter M., Ohno T., Gordon D., Nabel GJ, Nabel EG. (1996). Regulation of cellular proliferation and intimal formation following balloon injury in atherosclerotic rabbit arteries. J Clin Invest 98: 225–235.
62. 62 Somiari S., Glasspool‐Malone J., Drabick JJ, Gilbert RA, Heller R., Jaroszeski MJ, Malone RW. (2000). Theory and in vivo application of electroporative gene delivery. Mol Ther 2: 178–187.
63. 63 Stephan D., San H., Yang ZY, Gordon D., Goelz S., Nabel GJ, Nabel EG. (1997). Inhibition of vascular smooth muscle cell proliferation and intimal hyperplasia by gene transfer of beta‐interferon. Mol Med 3: 593–599.
64. 64 Takeshita S., Gal D., Leclerc G., Pickering JG, Riessen R., Weir L., Isner JM. (1994). Increased gene expression after liposome‐mediated arterial gene transfer associated with intimal smooth muscle cell proliferation. In vitro and in vivo findings in a rabbit model of vascular injury. J Clin Invest 93: 652–661.
65. 65 Tan Y., Liu F., Li Z., Li S., Huang L.. (2001). Sequential injection of cationic liposome and plasmid DNA effectively transfects the lung with minimal inflammatory toxicity. Mol Ther 3: 673–682.
66. 66 Tang MX, Szoka FC. (1997). The influence of polymer structure on the interactions of cationic polymers with DNA and morphology of the resulting complexes. Gene Ther 4: 823–832.
67. 67 Tanner FC, Yang ZY, Duckers E., Gordon D., Nabel GJ, Nabel EG. (1998). Expression of cyclin‐dependent kinase inhibitors in vascular disease. Circ Res 82: 396–403.
68. 68 Toyoda T., Imamura Y., Takaku H., Kashiwagi T., Hara K., Iwahashi J., Ohtsu Y., Tsumura N., Kato H., Hamada N.. (2000). Inhibition of influenza virus replication in cultured cells by RNA‐cleaving DNA enzyme. FEBS Lett 481: 113–116.
69. 69 Turunen MP, Hiltunen MO, Ruponen M., Virkamäki L., Szoka JFC, Urtti A., YläHerttuala S.. (1999). Efficient adventitial gene delivery to rabbit carotid artery with cationic polymer‐plasmid complexes. Gene Ther 6: 6–11.
70. 70 Tyler RC, Fagan KA, Unfer RC, Gorman C., McClarrion M., Bullock C., Rodman DM. (1999). Vascular inflammation inhibits gene transfer to the pulmonary circulation in vivo. Am J Physiol 277: L1199–L1204.
71. 71 Vacik J., Dean BS, Zimmer WE, Dean DA. (1999). Cell‐specific nuclear import of plasmid DNA. Gene Ther 6: 1006–1014.
72. 72 von der Leyen HE, Braun‐Dullaeus R., Mann MJ, Zhang L., Niebauer J., Dzau VJ. (1999). A pressure‐mediated nonviral method for efficient arterial gene and oligonucleotide transfer. Hum Gene Ther 10: 2355–2364.
73. 73 von der Leyen HE, Gibbons GH, Morishita R., Lewis NP, Zhang L., Nakajima M., Kaneda Y., Cooke JP, Dzau VJ. (1995). Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci USA 92: 1137–1141.
74. 74 Walther W., Stein U.. (2000). Viral vectors for gene transfer: a review of their use in the treatment of human diseases. Drugs 60: 249–271.
75. 75 Wang Y., Boros P., Liu J., Qin L., Bai Y., Bielinska AU, Kukowska‐Latallo JF, Baker JR Jr, Bromberg JS. (2000). DNA/dendrimer complexes mediate gene transfer into murine cardiac transplants ex vivo. Mol Ther 2: 602–608.
76. 76 Xiong Y., Hannon GJ, Zhang H., Casso D., Kobayashi R., Beach D.. (1993). p21 is a universal inhibitor of cyclin kinases. Nature 366: 701–704.
77. 77 Yang ZY, Simari RD, Perkins ND, San H., Gordon D., Nabel GJ, Nabel EG. (1996). Role of the p21 cyclin‐dependent kinase inhibitor in limiting cell proliferation in response to arterial injury. Proc Natl Acad Sci USA 93: 7905–7910.
78. 78 Yla‐Herttuala S., Martin JF. (2000). Cardiovascular gene therapy. Lancet 355: 213–222.
79. 79 Yonemitsu Y., Kaneda Y., Tanaka S., Nakashima Y., Komori K., Sugimachi K., Sueishi K.. (1998). Transfer of wild‐type p53 gene effectively inhibits vascular smooth muscle cell proliferation in vitro and in vivo. Circ Res 82: 147–156.
80. 80 Zabner J., Fasbender AJ, Moninger T., Poellinger KA, Welsh MJ. (1995). Cellular and molecular barriers to gene transfer by a cationic lipid. J Biol Chem 270: 18997–19007.
81. 81 Zhang G., Budker V., Williams P., Subbotin V., Wolff JA. (2001). Efficient expression of naked DNA delivered intraarterially to limb muscles of nonhuman primates. Hum Gene Ther 12: 427–438.
82. 82 Zhang G., Song YK, Liu D.. (2000). Long‐term expression of human alpha1‐antitrypsin gene in mouse liver achieved by intravenous administration of plasmid DNA using a hydrodynamics‐based procedure. Gene Ther 7: 1344–1349.
83. 83 Zhang X., Xu Y., Ling H., Hattori T.. (1999). Inhibition of infection of incoming HIV‐1 virus by RNA‐cleaving DNA enzyme. FEBS Lett 458: 151–156.